Overview

Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

Status:
Withdrawn
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of tirabrutinib in reducing disease activity in participants with chronic spontaneous urticaria (CSU) with respect to change from baseline in urticaria activity score over 7 days (UAS7) at Week 8 when added to standard of care.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences